Literature DB >> 28428726

Successful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.

Sheng Si1, Michael J Durkin2, Maureen M Mercier2, Melanie L Yarbrough3, Stephen Y Liang2,4.   

Abstract

Few antibiotic options exist for the management of infections due to vancomycin-resistant enterococci (VRE). We describe a case involving the safe and successful use of tedizolid, a new oxazolidinone, to treat VRE prosthetic joint infection.

Entities:  

Keywords:  prosthetic joint infection; tedizolid; vancomycin-resistant enterococci

Year:  2017        PMID： 28428726      PMCID： PMC5393450          DOI： 10.1097/IPC.0000000000000469

Source DB:  PubMed          Journal:  Infect Dis Clin Pract (Baltim Md)        ISSN： 1056-9103


  11 in total

Review 1.  Prosthetic joint infections.

Authors:  Irene G Sia; Elie F Berbari; Adolf W Karchmer
Journal:  Infect Dis Clin North Am       Date:  2005-12       Impact factor: 5.982

Review 2.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

3.  In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections.

Authors:  Suzannah M Schmidt-Malan; Kerryl E Greenwood Quaintance; Melissa J Karau; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2016-01-12       Impact factor: 2.803

4.  Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2013-01       Impact factor: 9.079

5.  Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.

Authors:  Katie E Barber; Jordan R Smith; Animesh Raut; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-10-16       Impact factor: 5.790

6.  Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Authors:  Andrew F Shorr; Thomas P Lodise; G Ralph Corey; Carisa De Anda; Edward Fang; Anita F Das; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

7.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

8.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

9.  Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006.

Authors:  Andrew M Ramsey; Marya D Zilberberg
Journal:  Infect Control Hosp Epidemiol       Date:  2009-02       Impact factor: 3.254

10.  In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.

Authors:  Ronda Schaadt; Debora Sweeney; Dean Shinabarger; Gary Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191
View more
  4 in total

1.  Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy.

Authors:  Matteo Bassetti; Nadia Castaldo; Alessia Carnelutti; Maddalena Peghin; Daniele Roberto Giacobbe
Journal:  Core Evid       Date:  2019-07-05

2.  Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs.

Authors:  Eva Benavent; Laura Morata; Francesc Escrihuela-Vidal; Esteban Alberto Reynaga; Laura Soldevila; Laia Albiach; Maria Luisa Pedro-Botet; Ariadna Padullés; Alex Soriano; Oscar Murillo
Journal:  Antibiotics (Basel)       Date:  2021-01-08

Review 3.  Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

Authors:  Darrell McBride; Tamara Krekel; Kevin Hsueh; Michael J Durkin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-16       Impact factor: 4.481

4.  Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project.

Authors:  Zaira R Palacios-Baena; Lucia Valiente de Santis; Natalia Maldonado; Clara M Rosso-Fernández; Irene Borreguero; Carmen Herrero-Rodríguez; Salvador López-Cárdenas; Franciso J Martínez-Marcos; Andrés Martín-Aspas; Patricia Jiménez-Aguilar; Juan J Castón; Francisco Anguita-Santos; Guillermo Ojeda-Burgos; M Pilar Aznarte-Padial; Julia Praena-Segovia; Juan E Corzo-Delgado; M Ángeles Esteban-Moreno; Jesús Rodríguez-Baño; Pilar Retamar
Journal:  BMJ Open       Date:  2020-07-31       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.